Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using non-denatured ethanol for RU58841. Treatments mentioned include Minoxidil, finasteride, and RU58841.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

Mixing RU58841 with a solution for hair loss treatment, with suggestions to use propylene glycol and ethanol instead of k&b solution due to scalp irritation. Recommendations include using ketoconazole shampoo for itchiness and considering oral minoxidil if topical causes irritation.

The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.

RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

User 74775446 shares successful hair regrowth results using dermaroller/pen and minoxidil. Others discuss their experiences and concerns about finasteride side effects.

Pyrilutamide is being used effectively for hair loss with no side effects, and the user is seeking a cheaper bulk supplier. Users discuss the difficulty of finding affordable, trustworthy sources, with some suggesting potential suppliers.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

A female user is using a 5% RU58841 solution with 5 sprays daily and is concerned about potential reactions and the impact of wearing a bonnet. A male user mentioned using 1ml of the same solution daily via dropper.

A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.

A 17-year-old is experiencing hairline recession and thinning, currently using minoxidil without success, and seeks to buy finasteride without needing ID. They are looking for legitimate websites to purchase finasteride.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.